The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Per the company ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of ...

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in ...